{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:20:31Z","timestamp":1791937231755,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.ajog.2011.12.029","type":"journal-article","created":{"date-parts":[[2011,12,30]],"date-time":"2011-12-30T21:39:11Z","timestamp":1325281151000},"page":"351.e1-351.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"title":["Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders"],"prefix":"10.1016","volume":"206","author":[{"given":"Richard G.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Craig","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret M.","family":"Steinhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Skates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen H.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geralyn","family":"Lambert-Messerlian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Robert C.","family":"Bast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2011.12.029_bib1","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI110380","article-title":"Reactivity of a monoclonal antibody with human ovarian carcinoma","volume":"68","author":"Bast","year":"1981","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajog.2011.12.029_bib2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM198310133091503","article-title":"A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer","volume":"309","author":"Bast","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajog.2011.12.029_bib3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/1096-9098(200012)75:4<264::AID-JSO7>3.0.CO;2-Q","article-title":"Benign conditions associated with raised serum CA-125 concentration","volume":"75","author":"Buamah","year":"2000","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ajog.2011.12.029_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/jso.2930560204","article-title":"Serum CA 125 concentrations in patients with benign ovarian tumours","volume":"56","author":"Buamah","year":"1994","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ajog.2011.12.029_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF00931312","article-title":"CA 125 in the serum and tissue of patients with gynecological disease","volume":"241","author":"Fuith","year":"1987","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.ajog.2011.12.029_bib6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/172460089801300411","article-title":"CA 125 in benign gynecological conditions","volume":"13","author":"Meden","year":"1998","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.ajog.2011.12.029_bib7","first-page":"703","article-title":"CA125 antigen levels in obstetric and gynecologic patients","volume":"64","author":"Niloff","year":"1984","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2011.12.029_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0090-8258(92)90082-T","article-title":"Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival","volume":"47","author":"Buller","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2011.12.029_bib9","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/bjc.1984.254","article-title":"Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker","volume":"50","author":"Canney","year":"1984","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajog.2011.12.029_bib10","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/bjc.1989.329","article-title":"The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma","volume":"60","author":"Hawkins","year":"1989","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajog.2011.12.029_bib11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/oxfordjournals.annonc.a057754","article-title":"The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer","volume":"1","author":"van der Burg","year":"1990","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajog.2011.12.029_bib12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0029-7844(95)00126-C","article-title":"Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer","volume":"86","author":"Nagele","year":"1995","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2011.12.029_bib13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/annonc\/mdm495","article-title":"Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer","volume":"19","author":"Prat","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajog.2011.12.029_bib14","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/annonc\/mdl120","article-title":"CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study","volume":"17","author":"Riedinger","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajog.2011.12.029_bib15","first-page":"287","article-title":"[Prognostic value of CA125 half-life and early normalization during chemotherapy in advanced ovarian tumors: results of a multicentric French study]","volume":"94","author":"Riedinger","year":"2007","journal-title":"Bull Cancer"},{"key":"10.1016\/j.ajog.2011.12.029_bib16","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","article-title":"Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125","volume":"14","author":"Rustin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajog.2011.12.029_bib17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygyno.2004.09.020","article-title":"CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma","volume":"96","author":"Tate","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2011.12.029_bib18","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1471-0528.1990.tb02448.x","article-title":"A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer","volume":"97","author":"Jacobs","year":"1990","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2011.12.029_bib19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"Moore","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2011.12.029_bib20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","article-title":"Comprehensive analysis of HE4 expression in normal and malignant human tissues","volume":"19","author":"Galgano","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ajog.2011.12.029_bib21","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","article-title":"Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas","volume":"65","author":"Drapkin","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajog.2011.12.029_bib22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2011.12.029_bib23","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstrom","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajog.2011.12.029_bib24","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ygyno.2010.02.005","article-title":"Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass","volume":"117","author":"Nolen","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"2 Part 1","key":"10.1016\/j.ajog.2011.12.029_bib25","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/AOG.0b013e318224fce2","article-title":"Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass","volume":"118","author":"Moore","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2011.12.029_bib26","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1158\/1055-9965.EPI-05-0334","article-title":"Mesothelin variant 1 is released from tumor cells as a diagnostic marker","volume":"15","author":"Hellstrom","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ajog.2011.12.029_bib27","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/sj.bjc.6605011","article-title":"Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts","volume":"100","author":"Huhtinen","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajog.2011.12.029_bib28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.fertnstert.2010.08.043","article-title":"CA 125 serum values in surgically treated endometriosis patients and its relationships with anatomic sites of endometriosis and pregnancy rate","volume":"95","author":"Patrelli","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2011.12.029_bib29","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/humrep\/deh890","article-title":"Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas","volume":"20","author":"Kitawaki","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ajog.2011.12.029_bib30","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/humrep\/dep425","article-title":"Non-invasive diagnosis of endometriosis based on a combined analysis of six plasma biomarkers","volume":"25","author":"Mihalyi","year":"2010","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ajog.2011.12.029_bib31","first-page":"341","article-title":"Pelvic inflammatory disease","volume":"41","author":"Moley","year":"1996","journal-title":"J Reprod Med"},{"key":"10.1016\/j.ajog.2011.12.029_bib32","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1093\/clinchem\/37.11.1968","article-title":"CA-125 concentrations in malignant and nonmalignant disease","volume":"37","author":"Daoud","year":"1991","journal-title":"Clin Chem"},{"key":"10.1016\/j.ajog.2011.12.029_bib33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0002-9378(88)80081-4","article-title":"Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease","volume":"159","author":"Malkasian","year":"1988","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2011.12.029_bib34","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1515\/CCLM.2011.085","article-title":"Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population","volume":"49","author":"Kim","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.ajog.2011.12.029_bib35","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1515\/CCLM.2011.075","article-title":"The ROMA (Risk of Ovarian Malignancy Algorithm) index for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?","volume":"49","author":"Montagnana","year":"2011","journal-title":"Clin Chem Lab Med"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937811024690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937811024690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T10:45:13Z","timestamp":1757587513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937811024690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0002937811024690"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2011.12.029","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2011.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}